Mei Ling Chong

Dr. Mei Ling Chong

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMona Makhamreh
Mona Makhamreh
MCMei Ling Chong
Mei Ling Chong
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
Advancements in genomic technologies have transformed prenatal genetic testing, offering more accurate, comprehensive, and noninvasive approaches to reproductive care. This review provides an in-depth overview of current methodologies and emerging innovations, including expanded carrier screening (ECS), cell-free DNA (cfDNA) testing, chromosomal microarray analysis (CMA), and sequencing-based diagnostics. We highlight how next-generation sequencing (NGS) technologies have revolutionized carrier screening and fetal genome analysis, enabling detection of a broad spectrum of genetic conditions. The clinical implementation of cfDNA has expanded from common aneuploidies to include copy number variants (CNVs), and single-gene disorders. Diagnostic testing has similarly evolved, with genome sequencing outperforming traditional CMA and exome sequencing through its ability to detect both sequence and structural variants in a single assay. Emerging tools such as optical genome mapping, RNA sequencing, and long-read sequencing further enhance diagnostic yield and variant interpretation. This review summarizes major technological advancements, assesses their clinical utility and limitations, and outlines future directions in prenatal genomics.

19 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMona Makhamreh
Mona Makhamreh
MCMei Ling Chong
Mei Ling Chong
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
Advancements in genomic technologies have transformed prenatal genetic testing, offering more accurate, comprehensive, and noninvasive approaches to reproductive care. This review provides an in-depth overview of current methodologies and emerging innovations, including expanded carrier screening (ECS), cell-free DNA (cfDNA) testing, chromosomal microarray analysis (CMA), and sequencing-based diagnostics. We highlight how next-generation sequencing (NGS) technologies have revolutionized carrier screening and fetal genome analysis, enabling detection of a broad spectrum of genetic conditions. The clinical implementation of cfDNA has expanded from common aneuploidies to include copy number variants (CNVs), and single-gene disorders. Diagnostic testing has similarly evolved, with genome sequencing outperforming traditional CMA and exome sequencing through its ability to detect both sequence and structural variants in a single assay. Emerging tools such as optical genome mapping, RNA sequencing, and long-read sequencing further enhance diagnostic yield and variant interpretation. This review summarizes major technological advancements, assesses their clinical utility and limitations, and outlines future directions in prenatal genomics.

1 December 2024 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
KLKhai Pang Leong
Khai Pang Leong
MYMei Yun Yong
Mei Yun Yong
EKEe Tzun Koh
Ee Tzun Koh
PCPeter Pak Moon Cheung
Peter Pak Moon Cheung
MLManjari Lahiri
Manjari Lahiri
TGthe Singapore Rheumatoid Arthritis Study Group.
the Singapore Rheumatoid Arthritis Study Group.
Objective: More than 130 susceptibility loci for rheumatoid arthritis (RA) have been identified with genome-wide association studies. To investigate the genetic predisposition of Chinese patients to anticitrullinated protein antibody (ACPA)-positive RA, we carried out an exome sequencing study.Methods: Patients were recruited from 3 major public hospitals in Singapore: Tan Tock Seng Hospital (TTSH), Singapore General Hospital, and the National University Hospital. Controls came from an established exome collection and from the TTSH Health Control Biobank. All the participants were of Chinese descent. We performed whole-exome sequencing (WES) in 595 ACPA-positive patients with RA and 1281 controls and validated the candidate variants by genotyping 795 RA cases and 600 controls.Results: The discovery cohort yielded 73 susceptibility single-nucleotide variants (SNVs) that reached statistical significance. In the validation study with an independent cohort, 2 SNVs remained significant:PCNXL4(P= 1.50 × 10–5) andDHRS7(P= 6.02 × 10–5). The majority of known susceptibility foci were not captured by exome sequencing.Conclusion: In this WES study of ACPA-positive RA in Chinese patients, we discovered 2 new variants inPCNXL4andDHRS7associated with risk for RA.